Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of ...

Patients with severe bowel disease are set to benefit from a new drug that can eliminate their distressing symptoms in only ...

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tremfya (guselkumab) (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC).

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC). Guselkumab is currently ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with ...